$10.350
-1.179 (-11.39%)收盘时
LEXX 资讯
LEXX 事件
Lexaria Bioscience Enters Material Transfer Agreement with Pegbio
Lexaria Bioscience announces that it has entered into a Material Transfer Agreement, MTA, with Pegbio to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company. The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1 molecule which will then be processed with Lexaria's patented DehydraTECH technology and evaluated for pharmacokinetic performance in animal studies.
Lexaria Bioscience Trading Halted Due to Volatility
Lexaria Bioscience Corp trading halted, volatility trading pause
Lexaria Bioscience to Implement 1-for-15 Reverse Stock Split on August 3, 2026
Lexaria Bioscience intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026. The primary goal of the Reverse Split is to increase the per Share market price of the Company's Shares with the objective of regaining compliance with the NASDAQ Capital Market's minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2). The Reverse Split is also being performed in an effort to stabilize uncertain stock conditions in the face of a number of critical business drivers which we believe to be in the best immediate and long-term interests of our shareholders. The Reverse Split will be conducted on a 1-for-15 basis resulting in the Company's current issued share capital of 24,787,446 shares of common stock being consolidated into 1,652,518 Shares, subject to further adjustment for fractional Shares which will be rounded up to the nearest whole number.
Lexaria Engages in Positive Meetings with Pharmaceutical Partners at 2026 BIO Convention
The company said, "Lexaria is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention in San Diego, CA...While new corporate relationships require time to identify areas of common interest and capabilities, including but not limited to technologic compatibility, we also continue to advance our pre-existing corporate relationships. While timelines and closure rates are impossible to predict, Lexaria remains optimistic about its prospects. Of note, most of Lexaria's business discussions are related to the GLP-1 sector and its many applications. Within the GLP-1 sector, Lexaria detected a notable shift in this year's BIO conference to a focus on drug safety and adverse event profiles, given the reality that certain drugs currently under development are approaching practical maximums of weight-loss efficacy. Both in public presentations as well as in our one-on-one meetings, a growing number of pharmaceutical companies are confirming that their focus has shifted towards finding a better balance between weight-loss efficacy, tolerability and safety. The idea that GLP-1 drugs can work effectively at the same time as minimizing unpleasant adverse events is consistent with both Lexaria's mission, and the capabilities of our DehydraTECH technology. In addition, Lexaria is pleased to report that interest in DehydraTECH technology is expanding once again outside of the GLP-1 industry. Lexaria has recently received renewed incoming corporate interest in the DehydraTECH-CBD and DehydraTECH-nicotine sectors where the Company has conducted extensive previous R&D validating the efficacy of the DehydraTECH technology."
Lexaria Bioscience Begins Human Pilot Study #7
Lexaria Bioscience (LEXX) announces that dosing began on schedule on June 14th with Human Pilot Study #7, GLP-1-H26-7, that is evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's (NVO) commercially available Wegovy tablets, over a 5-week duration.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。